Epoch Investment Partners Inc. Raises Stock Holdings in Lantheus Holdings, Inc. $LNTH

Epoch Investment Partners Inc. boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 59.4% in the first quarter, Holdings Channel.com reports. The firm owned 649,751 shares of the medical equipment provider’s stock after buying an additional 242,222 shares during the quarter. Epoch Investment Partners Inc.’s holdings in Lantheus were worth $49,284,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Smartleaf Asset Management LLC boosted its holdings in shares of Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC increased its stake in shares of Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock worth $36,000 after acquiring an additional 298 shares in the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Lantheus in the 2nd quarter worth about $36,000. Bessemer Group Inc. lifted its position in Lantheus by 221.2% during the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 354 shares during the period. Finally, Los Angeles Capital Management LLC purchased a new position in Lantheus during the 4th quarter valued at about $39,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Price Performance

LNTH opened at $104.82 on Friday. The firm has a market cap of $6.82 billion, a PE ratio of 25.26 and a beta of -0.06. The stock has a 50-day moving average price of $103.36 and a 200-day moving average price of $85.56. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $111.86. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.83 and a quick ratio of 2.64.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, beating the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million for the quarter, compared to the consensus estimate of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. Citizens Jmp reissued a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Truist Financial lifted their target price on shares of Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, July 16th. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a research report on Thursday, May 7th. Finally, Mizuho upped their price target on Lantheus from $115.00 to $120.00 and gave the stock a “market outperform” rating in a research note on Wednesday, July 15th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and a consensus price target of $110.43.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.